The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
Abstract
BACKGROUND: In the absence of an efficacious broadly protective vaccine, serogroup B Neisseria meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in many industrialized countries. An investigational recombinant vaccine that contains 3 central proteins; Neisserial adhesin A (NadA), factor H binding protein (fHBP) and Neisserial heparin binding antigen (NHBA) has been developed. These antigens have been formulated with and without outer membrane vesicles (rMenB+OMV and rMenB, respectively) from the New Zealand epidemic strain (B:4:P1.7-2,4). In this trial, we assessed the immunogenicity of these formulations in infants, who are at greatest risk of contracting MenB disease. METHODS: A total of 147 infants from the United Kingdom were enrolled and randomly assigned to receive rMenB or rMenB+OMV at 2, 4, 6, and 12 months of age or a single dose at 12 months of age. Serum samples taken before and after vaccination were assayed in a standardized serum bactericidal antibody assay against 7 MenB strains. Local and systemic reactogenicity were recorded for 7 days after each vaccination. Analysis was according to protocol. RESULTS: After 3 doses, both vaccines were immunogenic against strains expressing homologous or related NadA and fHBP. rMenB+OMV demonstrated greater immunogenicity than did rMenB and was immunogenic against strains expressing homologous PorA. Both vaccines elicited anamnestic responses after the fourth dose. For both vaccines, responses were lower against strains expressing heterologous fHBP variants and after a single dose at 12 months. CONCLUSIONS: The rMenB+OMV vaccine has the potential to protect infants from MenB disease, although the breadth of protection afforded to heterologous antigens requires additional investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS
Finne, J., Leinonen, M., & Mäkelä, P. H. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90340-9 · Cited by 796
A universal vaccine for serogroup B meningococcus
Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A., Capecchi, B., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603940103 · Cited by 727
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, Ø., Fredriksen, J. H., Lindbak, A.-K., Nøkleby, H., Rosenqvist, E., Solberg, L. K., Closs, O., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)91961-s · Cited by 694
Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R., & Terry, M. H. (1991) · PubMed · Cited by 512
Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines
Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., Berman, S. L., & Lowenthal, J. P. (1972) · Journal of Infectious Diseases · doi:10.1093/infdis/126.5.514 · Cited by 446
Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870
Masignani, V., Comanducci, M., Giuliani, M. M., Bambini, S., Adu-Bobie, J., Aricò, B., Brunelli, B., Pieri, A., Santini, L., Savino, S., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021911 · Cited by 395
Tappero, J. W., Lagos, R., Maldonado Ballesteros, A., Plikaytis, B., Williams, D., Dykes, J., Gheesling, L. L., Carlone, G. M., Høiby, E. A., Holst, J., et al. (1999) · JAMA · doi:10.1001/jama.281.16.1520 · Cited by 369
NadA, a Novel Vaccine Candidate of Neisseria meningitidis
Comanducci, M., Bambini, S., Brunelli, B., Adu-Bobie, J., Aricò, B., Capecchi, B., Giuliani, M. M., Masignani, V., Santini, L., Savino, S., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020407 · Cited by 351
Boslego, J. (1995) · Vaccine · doi:10.1016/0264-410x(94)00037-n · Cited by 267
Fredriksen, J. H., Rosenqvist, E., Wedege, E., Bryn, K., BJUNE, G., Frøholm, L. O., Lindbak, A.-K., Møgster, B., Namork, E., & Rye, U. (1991) · PubMed · Cited by 242
Cited by
Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.033 · Cited by 404
Gossger, N., Snape, M. D., Yu, L.-M., Finn, A., Bona, G., Esposito, S., Principi, N., Diez-Domingo, J., Sokal, E., Becker, B., et al. (2012) · JAMA · doi:10.1001/jama.2012.85 · Cited by 285
Self-citationAcute bacterial meningitis in adults
McGill, F., Heyderman, R. S., Panagiotou, S., Tunkel, A. R., & Solomon, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30654-7 · Cited by 274
Vesikari, T., Esposito, S., Prymula, R., Ypma, E., Kohl, I., Toneatto, D., Dull, P., & Kimura, A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61961-8 · Cited by 279
Self-citationSantolaya, M. E., O'Ryan, M. L., Valenzuela, M. T., Prado, V., Vergara, R., Muñoz, A., Toneatto, D., Graña, G., Wang, H., Clemens, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61713-3 · Cited by 260
Self-citationLadhani, S. N., Flood, J. S., Ramsay, M. E., Campbell, H., Gray, S. J., Kaczmarski, E. B., Mallard, R. H., Guiver, M., Newbold, L. S., & Borrow, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.011 · Cited by 124
Self-citationEmerging experience with meningococcal serogroup B protein vaccines
Toneatto, D., Pizza, M., Masignani, V., & Rappuoli, R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1308828 · Cited by 67
Self-citationZnuD, a Potential Candidate for a Simple and Universal Neisseria meningitidis Vaccine
Hubert, K., Devos, N., Mordhorst, I., Tans, C., Baudoux, G., Feron, C., Goraj, K., Tommassen, J., Vogel, U., Poolman, J. T., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01312-12 · Cited by 28
Metadata
- Authors
- Findlow, J., Borrow, R., Snape, M. D., Dawson, T., Holland, A., John, T. M., Evans, A., Telford, K. L., Ypma, E., Toneatto, D., Oster, P., Miller, E., & Pollard, A. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-15
- Volume
- 51
- Issue
- 10
- Pages
- 1127-1137
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2122656158
- Cited by
- 257
- References
- 18
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.